Founders pleaded guilty in 2024 to federal charges tied to misbranded and adulterated drugs. DOJ press release on file.
Below the routable line.
These vendors hit a sub-routable trigger (FDA action, federal conviction, permanent closure, etc.). Per Panya's policy, we don't gatekeep what users see. Vendors below the 70/100 routable line surface with their score and a risk disclosure block. For the most catastrophic categories with public-record evidence (regulatory enforcement, criminal conviction, permanent closure), the disclosure includes the vendor name.
26 vendors hit a sub-routable trigger. 5 are named below with evidence. The other 21 are bucketed by trigger category without names (defamation risk on naming without public record).
The documented cases.
These failures are on the public record. Naming them is not a defamation risk because the record exists. If any of these vendors have a successor entity in good standing that should not inherit the filter, that dispute goes to partner@panya.health.
Federal conviction of principals. Domain parked since enforcement action. No successor entity.
Voluntary closure announcement March 2026. Inventory liquidated. Domain redirects to holding page.
Permanent closure January 2026. Domain dead. Prior customers directed to submit refund requests via Discord (now also dark).
Cross-referenced 40+ purported independent reviews with identical phrasing patterns and creation timestamps. Review forensics failed.
The rest of the filter.
For vendors where the failure is real but the evidence is not publicly documented, naming would be a defamation risk and is also not the filter's purpose. The purpose is protecting the user. So we publish the trigger and the count, not the name.
Peptides shipped without refrigeration or temperature logs. No public controversy yet but the evidence trail is there.
Vendors who responded to COA requests with stonewalling or generic refusals.
Same-text reviews, timestamp clustering, or reviewer accounts with no other history.
Verified non-delivery without refund on multiple independent reports.
Sellers advertising GLP-1 as 'medical' without any clinical oversight.